Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Acarbose | Tesofensine | |
|---|---|---|
| Category | Pharmaceuticals | Pharmaceuticals |
| Standard Dose | Research indicates 25-100 mg taken with the first bite of each carbohydrate-containing meal, up to 3 times daily. | Research indicates 0.25-0.5 mg daily via oral administration. |
| Timing | Must be taken with the first bite of a carbohydrate-containing meal — timing is critical for mechanism of action. Ineffective if taken without carbohydrates or after the meal. | Morning dosing only. Avoid afternoon/evening dosing due to stimulant properties and potential insomnia. |
| Cycle Duration | Ongoing for longevity applications. Long-term use is well-established in diabetes management. | 12-24 week cycles. Monitor cardiovascular parameters throughout. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Acarbose is a complex oligosaccharide that competitively inhibits alpha-glucosidase enzymes (maltase, isomaltase, sucrase, glucoamylase) in the brush border of the small intestinal enterocytes, delaying the digestion and absorption of dietary carbohydrates. This blunts postprandial glucose and insulin spikes, reducing glycemic variability. In the longevity context, chronic postprandial glucose/insulin reduction mimics aspects of caloric restriction signaling, potentially reducing mTOR activation, AGE formation, and oxidative stress. Undigested carbohydrates reaching the colon serve as prebiotics, increasing short-chain fatty acid (SCFA) production by gut bacteria.
Research indicates 25-100 mg taken with the first bite of each carbohydrate-containing meal, up to 3 times daily.
Must be taken with the first bite of a carbohydrate-containing meal — timing is critical for mechanism of action. Ineffective if taken without carbohydrates or after the meal.
Ongoing for longevity applications. Long-term use is well-established in diabetes management.
Tesofensine (NS2330) is a triple monoamine reuptake inhibitor with affinity for dopamine (DAT), serotonin (SERT), and norepinephrine (NET) transporters. It suppresses appetite through indirect stimulation of alpha-1 adrenoceptor and dopamine D1 receptor pathways, reflecting additive effects of increased NE and DA activity. Tesofensine is a dual-action drug with both anorexigenic properties (appetite suppression) and metabolic properties (increased energy expenditure), silencing GABAergic hypothalamic neurons in the lateral hypothalamus.
Research indicates 0.25-0.5 mg daily via oral administration.
Morning dosing only. Avoid afternoon/evening dosing due to stimulant properties and potential insomnia.
12-24 week cycles. Monitor cardiovascular parameters throughout.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →